These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2412054)

  • 21. Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.
    Konishi M; Sakakura M; Tsushima N
    Cardiovasc Drugs Ther; 1990 Jan; 4 Suppl 1():101-4. PubMed ID: 2285638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-over study.
    Arneklo-Nobin B; Elmér O; Akesson A
    Int Angiol; 1988; 7(1):19-25. PubMed ID: 3290356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction.
    Jan KM; Powers E; Reinhart W; Berke A; Nichols A; Watson R; Reison D; Schwartz A; Chien S
    Adv Exp Med Biol; 1990; 281():409-17. PubMed ID: 2129379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin.
    Breuer J; Meschig R; Breuer HW; Arnold G
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S64-6. PubMed ID: 2412062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of serotonin and its antagonist ketanserin on pial vessels.
    Auer LM; Leber K; Sayama I
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):517-22. PubMed ID: 2932453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and of a specific antagonist.
    Jageneau AH; Hörig C; Loots W; Symoens J
    Angiology; 1980 Dec; 31(12):828-32. PubMed ID: 7469121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.
    Saman S; Thandroyen F; Opie LH
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S70-5. PubMed ID: 2412064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ketanserin on hemodynamics, plasma-catecholamine concentrations, and serotonin uptake by platelets in volunteers and patients with congestive heart failure.
    Grobecker H; Gessler I; Delius W; Dominiak P; Kees F
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S102-4. PubMed ID: 2412024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a selective 5-HT2 antagonist, ketanserin, on the pulmonary responses to Escherichia coli endotoxin.
    Ball HA; Parratt JR; Rodger IW
    Br J Pharmacol; 1983 Oct; 80(2):295-301. PubMed ID: 6360280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of serotonin antagonists on blood pressure in mineralocorticoid hypertensive sheep.
    Mecca TE; Mitchell J; Bohr DF; Webb RC
    J Cardiovasc Pharmacol; 1985; 7(4):660-5. PubMed ID: 2410705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of increased lung serotonin levels to endotoxin-induced pulmonary hypertension in sheep. Effect of a serotonin antagonist.
    Demling RH; Wong C; Fox R; Hechtman H; Huval W
    Am Rev Respir Dis; 1985 Dec; 132(6):1257-61. PubMed ID: 2934013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular pharmacology of ketanserin.
    Van Nueten JM; Vanhoutte PM
    Bibl Cardiol; 1984; (38):222-33. PubMed ID: 6099724
    [No Abstract]   [Full Text] [Related]  

  • 37. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
    Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
    Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired hemorheological properties in diabetic patients with lower limb arterial ischaemia.
    Le Devehat C; Khodabandehlou T; Vimeux M
    Clin Hemorheol Microcirc; 2001; 25(2):43-8. PubMed ID: 11790869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study with the competitive 5-HT2-serotonergic antagonist ketanserin.
    Ferrara LA; Fasano ML; Rubba P; Soro S; Marotta G; Mancini M
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S159-60. PubMed ID: 2412041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.